15 completed, 8 unknown, 3 active not recruiting, 2 terminated. 30 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 30 | Completed 15, Unknown 8, Active not recruiting 3, Terminated 2, Recruiting 1, Withdrawn 1 |
Follow Isoniazid: new trials by email Literature Review of Isoniazid trials Research Report on Isoniazid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Short-course Rifamycin-based Regimens for Latent Tuberculosis in Patients With End-stage Kidney Disease Rifampicin plus Isoniazid, Rifapentine plus Isoniazid, Rifampicin alone - Latent Tuberculosis, Kidney Failure | Phase 4 | Unknown | Miguel Santín | 225 | 2024-04-20 | 2024-03-15 |
| Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients Daily rifapentine and isoniazid for 4 weeks, Weekly rifapentine and isoniazid for 12 weeks - HIV Seropositivity, Tuberculosis | Phase 4 | Active not recruiting | The Aurum Institute NPC | 1000 | 2023-07-19 | 2025-12-12 |
| Efficacy Safety BaiDiZiYin ShenQiYiFei Adjunctive Treatments Pulmonary Tuberculosis BaiDiZiYin Pill, ShenQiYiFei Pill, Anti tuberculosis chemotherapy - Adjuvant, Treatment | Phase 4 | Recruiting | Beijing Chest Hospital | 292 | 2023-05-29 | 2024-05-08 |
| One-month Latent Tuberculosis Treatment for Renal Transplant Candidates 1 month Rifapentine, Isoniazid and Vitamin B6 - Latent Tuberculosis, End Stage Renal Disease | Phase 4 | Active not recruiting | Rutgers, The State University of New Jersey | 25 | 2022-07-01 | 2026-01-21 |
| Ultra Curto (Ultra Short) TB Prevention Therapy Rifapentine 600 mg and INH 300 mg, Rifapentine 900 mg and INH 900 mg - Tuberculosis | Phase 4 | Completed | Johns Hopkins University | 531 | 2022-03-24 | 2025-06-19 |
| Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation Rifampicin 300 Mg Oral Capsule, Isoniazid 300 Mg ORAL TABLET - Latent Tuberculosis, Diabetes Mellitus, Type 2 | Phase 4 | Completed | Herlev and Gentofte Hospital | 32 | 2021-04-15 | 2023-05-16 |
| Vaginal Isonicotinic Acid Hydrazide Prior to Diagnostic Office Hysteroscopy in Primarily Infertile Patients INH, Placebo - Infertility, Female | Phase 4 | Completed | Aswan University Hospital | 150 | 2020-09-01 | 2021-09-29 |
| Vaginal Isonicotinic Acid Hydrazide (INH) Administration Prior to T380A Intrauterine Device Insertion INH, Placebo Comparator - IUCD Complication | Phase 4 | Completed | Aswan University Hospital | 220 | 2020-09-01 | 2021-08-09 |
| Efficacy, Security, Adherence, Tolerability and Cost Effectiveness of Latent TB Treatment in Patients With TB/DM2 (TBL) Isoniazid 300 mg Oral Tablet, Rifampin 600 mg Oral Tablet - Diabetes Mellitus, Tuberculin (Skin Test) Positive | Phase 4 | Completed | Instituto Nacional de Salud Publica, Mexico | 396 | 2019-02-28 | 2019-04-26 |
| Latent Tuberculosis in Type 2 Diabetes Rifapentine and Isoniazid for 3 months, Isoniazid (INH) daily for 9 months - Latent Tuberculosis Infection | Phase 4 | Active not recruiting | Taichung Veterans General Hospital | 552 | 2018-04-18 | 2025-03-13 |
| Treatment of Latent Tuberculosis in Socially Marginalised Citizens Rifapentine, Isoniazid - Compliance, Patient | Phase 4 | Terminated | Aarhus University Hospital | 22 | 2017-10-27 | 2023-10-12 |
| Alcohol Drinkers' Exposure to Preventive Therapy for TB (ADEPTT) Isoniazid 300 Mg ORAL TABLET, Pyridoxine 25 Mg Oral Tablet - Tuberculosis, HIV/AIDS | Phase 4 | Completed | University of California, San Francisco | 302 | 2017-04-07 | 2023-10-19 |
| Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis Isoniazid, Rifampicin, Pyrazinamide - Tuberculosis, Pulmonary | Phase 4 | Unknown | Beijing Chest Hospital | 3900 | 2016-08-01 | 2017-03-20 |
| The Optimal Duration of Preoperative Anti-tuberculosis Treatment of Spinal Tuberculosis Isoniazid, Rifampicin, Ethambutol - Tuberculosis, Spinal | Phase 4 | Unknown | Beijing Chest Hospital | 400 | 2015-04-01 | 2015-06-23 |
| Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3 Xpert MTB/RIF®, Determine TB LAM, Chest X-ray, ART (Atripla, Truvada, Efavirenz, Combivir), Rifampin, isoniazid, pyrazinamide, ethambutol - HIV-1 Infection | Phase 4 | Completed | ANRS, Emerging Infectious Diseases | 1050 | 2014-09-01 | 2020-10-19 |
| Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women Isoniazid (INH), Placebo for isoniazid (INH) - HIV Infections, Tuberculosis | Phase 4 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 956 | 2014-08-19 | 2021-11-05 |
| Research on New Regimens for Retreatment Pulmonary Tuberculosis Isoniazid Aminosalicylate Tablets, Streptomycin injectable - Reinfection Pulmonary Tuberculosis | Phase 4 | Unknown | Shanghai Pulmonary Hospital, Shanghai, China | 864 | 2013-06-01 | 2015-01-06 |
| Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes Rifampicin, Isoniazid, Ethambutol, Pyrazinamide - AIDS With Tuberculosis | Phase 4 | Unknown | Makerere University | 400 | 2013-02-01 | 2015-04-13 |
| Evaluation of Diabetes Control and Effect on Transmission and Development of Tuberculosis Isoniazid 300Mg Tab, Isoniazid 300 MG - Latent Tuberculosis, Diabetes Mellitus | Phase 4 | Withdrawn | Instituto Nacional de Salud Publica, Mexico | 2012-09-01 | 2018-04-17 | |
| REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment Atripla (r), Efavirenz, Truvada - HIV Infection | Phase 4 | Completed | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 851 | 2011-10-01 | 2024-10-15 |
Showing 20 of 30. Sign in to see all of them.
Tuberculosis (18) · Latent Tuberculosis (10) · Acquired Immunodeficiency Syndrome (5) · HIV Infections (5) · Diabetes Mellitus (3) · Tuberculosis, Pulmonary (3) · Alcoholism (1) · Diabetes Mellitus, Type 2 (1) · HIV Seropositivity (1) · Hepatitis (1) · Infertility, Female (1) · Kidney Failure, Chronic (1) · Latent Infection (1) · Patient Compliance (1) · Renal Insufficiency (1)
Instituto Nacional de Salud Publica, Mexico (4) · Beijing Chest Hospital (3) · Aswan University Hospital (2) · National Taiwan University Hospital (2) · Sociedad Andaluza de Enfermedades Infecciosas (2) · ANRS, Emerging Infectious Diseases (1) · Aarhus University Hospital (1) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1) · Centers for Disease Control and Prevention (1) · Herlev and Gentofte Hospital (1) · Hospital Universitari de Bellvitge (1) · Hospital Virgen de la Luz (1) · Johns Hopkins University (1) · Makerere University (1) · Miguel Santín (1)
Uganda (5) · China (4) · Spain (4) · India (3) · Mexico (3) · South Africa (3) · Taiwan (3) · Botswana (2) · Brazil (2) · Denmark (2) · Egypt (2) · Haiti (2) · Zimbabwe (2) · Cambodia (1) · Côte d’Ivoire (1)
Antonio Rivero, MD PhD (2) · Felipes Diez, MD (2) · Fernando Lozano, MD PhD (2) · Jose Carlos Escribano, MD (2) · Juan Jose Hernandez, MD (2) · Juan Pasquau, MD (2) · Manuel Marquez, MD (2) · Rafael Castillo, MD (2) · Alfredo Ponce-de-Leon, MD (1)
PMID 25359354, PMID 12809582, PMID 17504682, PMID 21492926, PMID 21541021, PMID 22046230, PMID 23150149, PMID 23317952, PMID 23533318, PMID 25340318, PMID 27025337, PMID 28399802, PMID 28629333, PMID 28928173, PMID 29020191, PMID 29162063, PMID 29514175, PMID 29519716, PMID 30910890, PMID 31577875, PMID 31761933, PMID 32558469, PMID 33146706, PMID 36044285, PMID 36269714, PMID 36883573, PMID 37634517, PMID 38918780, PMID 39350021, PMID 41666121
2009 (1), U01AI068636 (1), U01AI152961 (1)